ACCESS TO INNOVATION

The cancer societies of this task force state that all effective and innovative cancer treatments now and in the future should be accessible to patients. Patients cannot suffer from a dysfunctional system and/or unsustainable financial and pricing arrangements in the prescription of medicines.

FAIR PRICES

Medicine prices should be sustainable and proportionate to real cost of research and development and added therapeutic value. In that respect an open, transparent and continuous dialogue with the pharmaceutical industry is needed. Knowledge and information must be shared internationally and co-operation must be sought after.

INFORMED PATIENT

Cancer medicines that have a distinctive therapeutic added value should reach patients in a timely manner, in the safest way and at affordable prices. The patients should be fully informed of the possible benefits and harms.

EU ADVOCACY

Cancer societies in Europe should work together to get and keep this issue on the national and European agendas of politicians, policy makers and the pharmaceutical industry.

PATIENT EMPOWERMENT

Patients should at all times be involved in the decision-making process (eg. joint decision making concerning policies as well as treatment process).